(Q36222128)

12 August 2017

1 reference

title

Thalidomide: dermatological indications, mechanisms of action and side-effects (English)

1 reference

12 August 2017

0 references

J J Wu

1

1 reference

12 August 2017

D B Huang

2

1 reference

12 August 2017

K R Pang

3

1 reference

12 August 2017

S Hsu

4

1 reference

12 August 2017

S K Tyring

5

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

British Journal of Dermatology

12 August 2017

published in

1 reference

12 August 2017

volume

153

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

254-273

1 reference

Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: discordant effects on minimal erythema dose and sunburn cell formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Effectors of inflammation in actinic prurigo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Isolated vulvar Langerhans cell histiocytosis: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Langerhans cell histiocytosis in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

[Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide for chronic sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Treatment of cutaneous sarcoidosis with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Recalcitrant erosive flexural lichen planus: successful treatment with a combination of thalidomide and 0.1% tacrolimus ointment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide-induced remission of lichen planopilaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Lichen planopilaris treated with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide is ineffective in the treatment of lichen planopilaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Treatment of metastatic melanoma in the brain with temozolomide and thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Phase II study of thalidomide in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

21 January 2018

Thalidomide embryopathy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Hypothesis: thalidomide embryopathy-proposed mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide neuropathy: an electrophysiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide-associated deep vein thrombosis and pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide-induced amenorrhoea: two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide and sexual dysfunction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Exacerbation of psoriasis by thalidomide in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide hypersensitivity in AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Dermatologic side effects of thalidomide in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide usage in Wales: the need to follow guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Behçet's disease in UK children: clinical features and treatment including thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

The use of thalidomide in chronic refractory graft versus host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte subpopulation numbers in female B6C3F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2005.06747.X

10.1111/J.1365-2133.2005.06747.X

21 January 2018

Identifiers

DOI

1 reference

release_3ulpvufwbzbbvjclou4b2s6b2m

12 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3ulpvufwbzbbvjclou4b2s6b2m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference